CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: FBXO27 (ImmuneEditome ID:126433)

1. Gene summary of enriched editing regions for FBXO27

check button Gene summary
Gene informationGene symbol

FBXO27

Gene ID

126433

GeneSynonymsFBG5|Fbx27
GeneCytomap

19q13.2

GeneTypeprotein-coding
GeneDescriptionF-box only protein 27|F-box protein FBG5|F-box/G-domain protein 5|epididymis secretory sperm binding protein
GeneModificationdate20230517
UniprotIDA0A384MR61;Q8NI29;M0QYQ6;M0R1C3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:39006121-39006880:-ENST00000598394.1ENSG00000161243.7FBXO27intronicAluSp,MER68-int,AluJo,L1MC4,AluSzchr19:39006121-39006880:-.alignment
chr19:39007793-39010131:-ENST00000598394.1ENSG00000161243.7FBXO27intronicAluSx1,L1MB7,FLAM_A,AluSx,MER68-int,AluJbchr19:39007793-39010131:-.alignment
chr19:39011138-39014036:-ENST00000598394.1ENSG00000161243.7FBXO27intronicAluY,AluSp,L1MB7,(AAAC)n,AluSx,MER68-int,AluJrchr19:39011138-39014036:-.alignment
chr19:39024335-39024845:-ENST00000509137.5ENSG00000161243.7FBXO27splicingAluJo,AluSxchr19:39024335-39024845:-.alignment


Top

2. Tumor-specific enriched editing regions for FBXO27


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000161243.7,FBXO27STADEAG8.5795e-047.8391e-036.5849e+02image

Top

3. Enriched editing regions and immune related genes for FBXO27


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for FBXO27


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for FBXO27


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:39007793-39010131:-BLCAEERMast_cells_resting4.1271e-020.3021image
chr19:39011138-39014036:-BLCAEERDendritic_cells_resting1.3885e-02-0.1954image
ENSG00000161243.7,FBXO27BLCAEAGDendritic_cells_activated1.5557e-020.1916image
chr19:39006121-39006880:-BRCAEERMonocytes3.7547e-020.4459image
chr19:39007793-39010131:-BRCAEERMast_cells_resting4.8146e-050.4659image
chr19:39011138-39014036:-BRCAEERMast_cells_resting4.6320e-030.1886image
ENSG00000161243.7,FBXO27BRCAEAGMast_cells_resting1.5875e-020.1420image
chr19:39011138-39014036:-CESCEERMast_cells_resting2.0489e-020.2375image
ENSG00000161243.7,FBXO27CESCEAGMast_cells_resting1.4808e-020.2456image
chr19:39007793-39010131:-ESCAEERNeutrophils6.7617e-040.5148image
chr19:39011138-39014036:-ESCAEERNK_cells_activated1.0754e-020.3075image
ENSG00000161243.7,FBXO27ESCAEAGNeutrophils7.6989e-030.3138image
chr19:39011138-39014036:-HNSCEERT_cells_CD82.6391e-030.2541image
ENSG00000161243.7,FBXO27HNSCEAGT_cells_CD81.1510e-020.2123image
chr19:39011138-39014036:-KIRCEERB_cells_naive1.8126e-020.3205image
ENSG00000161243.7,FBXO27KIRCEAGB_cells_naive3.1521e-020.2691image
chr19:39011138-39014036:-KIRPEERNK_cells_resting1.0539e-020.3952image
ENSG00000161243.7,FBXO27KIRPEAGNK_cells_resting2.5540e-020.3096image
chr19:39011138-39014036:-LGGEERT_cells_gamma_delta1.9592e-050.4501image
ENSG00000161243.7,FBXO27LGGEAGT_cells_gamma_delta6.8454e-060.3962image
ENSG00000161243.7,FBXO27LIHCEAGMacrophages_M22.6527e-02-0.2276image
ENSG00000161243.7,FBXO27LUADEAGEosinophils3.4955e-020.3477image
chr19:39011138-39014036:-LUSCEERT_cells_regulatory_(Tregs)3.4613e-020.1342image
ENSG00000161243.7,FBXO27LUSCEAGMonocytes1.1308e-02-0.1593image
chr19:39006121-39006880:-OVEERT_cells_regulatory_(Tregs)4.7388e-03-0.5675image
chr19:39007793-39010131:-OVEERT_cells_gamma_delta5.4698e-030.3544image
chr19:39024335-39024845:-OVEERNK_cells_activated1.5733e-030.6456image
ENSG00000161243.7,FBXO27OVEAGMacrophages_M08.3120e-03-0.2409image
ENSG00000161243.7,FBXO27PRADEAGDendritic_cells_activated2.9349e-050.5006image
ENSG00000161243.7,FBXO27SARCEAGDendritic_cells_activated2.1176e-030.5960image
chr19:39011138-39014036:-STADEERMast_cells_resting2.4582e-030.4501image
ENSG00000161243.7,FBXO27STADEAGMast_cells_resting1.0555e-030.3886image
ENSG00000161243.7,FBXO27THYMEAGPlasma_cells1.2183e-020.5364image
chr19:39011138-39014036:-UCECEERDendritic_cells_activated1.8063e-020.5104image


Top

6. Enriched editing regions and immune gene sets for FBXO27


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000161243.7,FBXO27BLCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.9653e-020.1849image
chr19:39011138-39014036:-BLCAGSVA_HALLMARK_G2M_CHECKPOINTEER9.2209e-030.2066image
chr19:39007793-39010131:-BLCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.3563e-030.4236image
chr19:39006121-39006880:-BRCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER6.5490e-030.5615image
ENSG00000161243.7,FBXO27BRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.9509e-030.1746image
chr19:39011138-39014036:-BRCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.2021e-030.1906image
chr19:39007793-39010131:-BRCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.4253e-030.3740image
ENSG00000161243.7,FBXO27ESCAGSVA_HALLMARK_SPERMATOGENESISEAG2.0077e-02-0.2754image
chr19:39011138-39014036:-ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.9994e-020.2634image
chr19:39007793-39010131:-ESCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.8694e-020.3461image
chr19:39011138-39014036:-KIRCGSVA_HALLMARK_ANGIOGENESISEER4.2957e-020.2765image
chr19:39011138-39014036:-KIRPGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER2.1490e-03-0.4658image
ENSG00000161243.7,FBXO27KIRPGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG4.1870e-02-0.2832image
ENSG00000161243.7,FBXO27LGGGSVA_HALLMARK_SPERMATOGENESISEAG4.4467e-020.1830image
chr19:39011138-39014036:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.0304e-020.1376image
chr19:39006121-39006880:-LUSCGSVA_HALLMARK_E2F_TARGETSEER7.1317e-030.4241image
chr19:39006121-39006880:-OVGSVA_HALLMARK_HEME_METABOLISMEER2.3191e-02-0.4713image
ENSG00000161243.7,FBXO27OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.3743e-030.2901image
chr19:39011138-39014036:-OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.3653e-04-0.3538image
chr19:39024335-39024845:-OVGSVA_HALLMARK_DNA_REPAIREER2.1511e-020.4983image
chr19:39007793-39010131:-OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER5.8858e-040.4309image
chr19:39011138-39014036:-PCPGGSVA_HALLMARK_UV_RESPONSE_DNEER4.7669e-020.2708image
ENSG00000161243.7,FBXO27PCPGGSVA_HALLMARK_G2M_CHECKPOINTEAG3.9728e-020.2663image
ENSG00000161243.7,FBXO27PRADGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.6101e-02-0.3021image
ENSG00000161243.7,FBXO27STADGSVA_HALLMARK_MYOGENESISEAG9.9269e-030.3106image
chr19:39011138-39014036:-STADGSVA_HALLMARK_MYOGENESISEER8.5040e-030.3964image
chr19:39011138-39014036:-UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.1275e-020.4488image


Top

7. Enriched editing regions and drugs for FBXO27


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:39011138-39014036:-BLCACHIR.99021EER1.2980e-030.2537image
chr19:39007793-39010131:-BLCAA.770041EER3.0858e-02-0.3187image
ENSG00000161243.7,FBXO27BLCACHIR.99021EAG1.2435e-030.2538image
ENSG00000161243.7,FBXO27BRCAAG.014699EAG7.6200e-03-0.1570image
chr19:39007793-39010131:-BRCAMethotrexateEER1.2919e-030.3771image
chr19:39006121-39006880:-BRCAGDC0941EER2.3682e-02-0.4803image
chr19:39011138-39014036:-BRCAAG.014699EER1.3473e-03-0.2129image
chr19:39011138-39014036:-CESCCGP.60474EER4.5660e-02-0.2056image
ENSG00000161243.7,FBXO27ESCABMS.708163EAG6.2572e-05-0.4567image
chr19:39011138-39014036:-ESCACMKEER4.9912e-04-0.4110image
chr19:39007793-39010131:-ESCABMS.708163EER8.9492e-04-0.5048image
chr19:39011138-39014036:-HNSCAZD.2281EER1.4065e-02-0.2086image
ENSG00000161243.7,FBXO27HNSCAZD.2281EAG7.4888e-03-0.2243image
ENSG00000161243.7,FBXO27KIRCGemcitabineEAG2.2933e-02-0.2840image
chr19:39011138-39014036:-LGGAZD6244EER2.2789e-02-0.2497image
ENSG00000161243.7,FBXO27LGGABT.888EAG1.6682e-02-0.2173image
chr19:39011138-39014036:-LIHCCEP.701EER1.1002e-02-0.2699image
ENSG00000161243.7,FBXO27LIHCCGP.60474EAG1.7678e-02-0.2430image
ENSG00000161243.7,FBXO27LUADCEP.701EAG1.1485e-03-0.5136image
chr19:39011138-39014036:-LUADCEP.701EER1.1638e-03-0.5560image
chr19:39011138-39014036:-LUSCCEP.701EER4.3425e-03-0.1805image
ENSG00000161243.7,FBXO27LUSCEpothilone.BEAG9.2286e-03-0.1637image
chr19:39006121-39006880:-LUSCDocetaxelEER6.7389e-03-0.4268image
chr19:39007793-39010131:-LUSCEtoposideEER2.9698e-030.2913image
chr19:39006121-39006880:-OVDMOGEER2.0455e-020.4800image
ENSG00000161243.7,FBXO27OVBMS.708163EAG3.3585e-04-0.3233image
chr19:39011138-39014036:-OVAZD6244EER2.3669e-05-0.4191image
chr19:39024335-39024845:-OVEmbelinEER7.3028e-030.5674image
chr19:39007793-39010131:-OVBMS.708163EER6.4953e-03-0.3476image
ENSG00000161243.7,FBXO27PCPGGNF.2EAG4.4291e-020.2606image
chr19:39011138-39014036:-PCPGAZD.2281EER4.4614e-030.3812image
ENSG00000161243.7,FBXO27PRADATRAEAG9.3407e-04-0.4069image
ENSG00000161243.7,FBXO27SARCMetforminEAG2.7077e-02-0.4507image
ENSG00000161243.7,FBXO27STADGSK269962AEAG1.3890e-04-0.4520image
chr19:39011138-39014036:-STADGSK269962AEER6.9902e-04-0.5023image
ENSG00000161243.7,FBXO27THYMAZD.0530EAG1.2003e-02-0.5374image
ENSG00000161243.7,FBXO27UCECMidostaurinEAG7.9081e-030.5000image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType